Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

DSpace Repository

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Author: Chng, W-J; Goldschmidt, H.; Dimopoulos, M. A.; Moreau, P.; Joshua, D.; Palumbo, A.; Facon, T.; Ludwig, H.; Pour, L.; Niesvizky, R.; Oriol, A.; Rosinol, L.; Suvorov, A.; Gaidano, G.; Pika, T.; Weisel, K.; Goranova-Marinova, V.; Gillenwater, H. H.; Mohamed, N.; Feng, S.; Aggarwal, S.; Hajek, R.
Tübinger Autor(en):
Weisel, Katja
Published in: Leukemia (2017), Bd. 31, H. 6, S. 1368-1374
Verlagsangabe: Nature Publishing Group
Language: English
Full text: http://dx.doi.org/10.1038/leu.2016.390
ISSN: 1476-5551
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)